125 related articles for article (PubMed ID: 10671667)
1. In vivo chemosensitivity of human malignant cystosarcoma phyllodes xenografts.
Ueyama Y; Abe Y; Ohnishi Y; Sawa N; Hatanaka H; Handa A; Tokuda Y; Yamazaki H; Kijima H; Tamaoki N; Nakamura M
Oncol Rep; 2000; 7(2):257-60. PubMed ID: 10671667
[TBL] [Abstract][Full Text] [Related]
2. Correlation between functional and molecular analysis of mdr1 P-glycoprotein in human solid-tumor xenografts.
Broxterman HJ; Feller N; Kuiper CM; Boven E; Versantvoort CH; Teerlink T; Pinedo HM; Lankelma J
Int J Cancer; 1995 Jun; 61(6):880-6. PubMed ID: 7790125
[TBL] [Abstract][Full Text] [Related]
3. Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts.
Kolfschoten GM; Hulscher TM; Pinedo HM; Boven E
Br J Cancer; 2000 Oct; 83(7):921-7. PubMed ID: 10970695
[TBL] [Abstract][Full Text] [Related]
4. Advantage of in vivo chemosensitivity assay to detect vincristine-resistance in a human epidermoid carcinoma xenograft.
Abe Y; Yamazaki H; Oshika Y; Suto R; Tsugu A; Ota E; Satoh H; Ohnishi Y; Yanagawa T; Ueyama Y; Tamaoki N; Nakamura M
Anticancer Res; 1996; 16(2):729-34. PubMed ID: 8687121
[TBL] [Abstract][Full Text] [Related]
5. A malignant cystosarcoma phyllodes with positive estrogen receptor and its heterotransplantation into nude mice.
Tokuda Y; Kubota M; Ueyama Y; Maruo K; Hata J; Tamaoki N; Tajima T; Mitomi T
Cancer; 1985 Jan; 55(2):370-4. PubMed ID: 2981144
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
7. Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody.
Fogler WE; Pearson JW; Volker K; Ariyoshi K; Watabe H; Riggs CW; Wiltrout RH; Longo DL
J Natl Cancer Inst; 1995 Jan; 87(2):94-104. PubMed ID: 7707396
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and pharmacological characterization of MCF-7 drug-sensitive and AdrR multidrug-resistant human breast tumor xenografts in athymic nude mice.
Mimnaugh EG; Fairchild CR; Fruehauf JP; Sinha BK
Biochem Pharmacol; 1991 Jul; 42(2):391-402. PubMed ID: 1677569
[TBL] [Abstract][Full Text] [Related]
9. Biochemical modulation of 'classical' multidrug resistance by BIBW22BS, a potent derivative of dipyridamole.
Jansen WJ; Pinedo HM; Kuiper CM; Lincke C; Bamberger U; Heckel A; Boven E
Ann Oncol; 1994 Oct; 5(8):733-9. PubMed ID: 7826906
[TBL] [Abstract][Full Text] [Related]
10. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
Stein U; Walther W; Shoemaker RH
J Natl Cancer Inst; 1996 Oct; 88(19):1383-92. PubMed ID: 8827016
[TBL] [Abstract][Full Text] [Related]
11. Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas.
Hoffmann J; Schmidt-Peter P; Hänsch W; Naundorf H; Bunge A; Becker M; Fichtner I
Clin Cancer Res; 1999 Aug; 5(8):2198-204. PubMed ID: 10473106
[TBL] [Abstract][Full Text] [Related]
12. Organoid models derived from patients with malignant phyllodes tumor of the breast.
Chu X; Wu M; Yang J; Fu Y; Wang X; Wang H; Xiao Y; Chen D; He J
Breast Cancer Res Treat; 2023 Jul; 200(2):193-201. PubMed ID: 37204665
[TBL] [Abstract][Full Text] [Related]
13. Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates.
Poupon MF; Arvelo F; Goguel AF; Bourgeois Y; Jacrot M; Hanania N; Arriagada R; Le Chevalier T
J Natl Cancer Inst; 1993 Dec; 85(24):2023-9. PubMed ID: 7902445
[TBL] [Abstract][Full Text] [Related]
14. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
Vredenburg MR; Ojima I; Veith J; Pera P; Kee K; Cabral F; Sharma A; Kanter P; Greco WR; Bernacki RJ
J Natl Cancer Inst; 2001 Aug; 93(16):1234-45. PubMed ID: 11504769
[TBL] [Abstract][Full Text] [Related]
15. PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein.
Vanhoefer U; Cao S; Minderman H; Tóth K; Scheper RJ; Slovak ML; Rustum YM
Clin Cancer Res; 1996 Feb; 2(2):369-77. PubMed ID: 9816180
[TBL] [Abstract][Full Text] [Related]
16. Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter.
Qiu JG; Zhang YJ; Li Y; Zhao JM; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Yang Y; Zheng DW; Chen Y; Wei MN; Shi Z
Oncotarget; 2015 Jun; 6(17):15494-509. PubMed ID: 25915534
[TBL] [Abstract][Full Text] [Related]
17. A new quinoline derivative MS-209 reverses multidrug resistance and inhibits multiorgan metastases by P-glycoprotein-expressing human small cell lung cancer cells.
Nokihara H; Yano S; Nishioka Y; Hanibuchi M; Higasida T; Tsuruo T; Sone S
Jpn J Cancer Res; 2001 Jul; 92(7):785-92. PubMed ID: 11473730
[TBL] [Abstract][Full Text] [Related]
18. [Studies on the in vivo and in vitro chemosensitivity tests using human tumor xenografts].
Yamada Y; Yamada T; Asanuma F; Suzuki T; Kawamura E
Hum Cell; 1995 Dec; 8(4):179-84. PubMed ID: 8721088
[TBL] [Abstract][Full Text] [Related]
19. Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening.
Boven E; Pinedo HM; van Hattum AH; Scheffer PG; Peters WH; Erkelens CA; Schlüper HM; Kuiper CM; van Ark-Otte J; Giaccone G
Br J Cancer; 1998 Dec; 78(12):1586-93. PubMed ID: 9862568
[TBL] [Abstract][Full Text] [Related]
20. MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer.
Leonessa F; Green D; Licht T; Wright A; Wingate-Legette K; Lippman J; Gottesman MM; Clarke R
Br J Cancer; 1996 Jan; 73(2):154-61. PubMed ID: 8546900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
